AR242832A1 - Polidomas productores de anticuerpos monoclonales hibridos biespecificos contra la fibrina y uk y/o pro uk y metodo para producirlos. - Google Patents

Polidomas productores de anticuerpos monoclonales hibridos biespecificos contra la fibrina y uk y/o pro uk y metodo para producirlos.

Info

Publication number
AR242832A1
AR242832A1 AR89314993A AR31499389A AR242832A1 AR 242832 A1 AR242832 A1 AR 242832A1 AR 89314993 A AR89314993 A AR 89314993A AR 31499389 A AR31499389 A AR 31499389A AR 242832 A1 AR242832 A1 AR 242832A1
Authority
AR
Argentina
Prior art keywords
polydomes
monoclone
pro
producing
bodies against
Prior art date
Application number
AR89314993A
Other languages
English (en)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of AR242832A1 publication Critical patent/AR242832A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AR89314993A 1988-09-27 1989-09-25 Polidomas productores de anticuerpos monoclonales hibridos biespecificos contra la fibrina y uk y/o pro uk y metodo para producirlos. AR242832A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP24354488 1988-09-27
JP30192588 1988-11-28
JP6294089 1989-03-14
JP16487389 1989-06-27
JP20893689A JP3177776B2 (ja) 1988-09-27 1989-08-11 ハイブリッドモノクローナル抗体,抗体産生ポリドーマおよび抗体含有薬剤

Publications (1)

Publication Number Publication Date
AR242832A1 true AR242832A1 (es) 1993-05-31

Family

ID=27523741

Family Applications (1)

Application Number Title Priority Date Filing Date
AR89314993A AR242832A1 (es) 1988-09-27 1989-09-25 Polidomas productores de anticuerpos monoclonales hibridos biespecificos contra la fibrina y uk y/o pro uk y metodo para producirlos.

Country Status (15)

Country Link
US (1) US5506135A (es)
EP (1) EP0363712B1 (es)
JP (1) JP3177776B2 (es)
KR (1) KR900004351A (es)
CN (1) CN1041783A (es)
AR (1) AR242832A1 (es)
AT (1) ATE140930T1 (es)
AU (1) AU628857B2 (es)
DE (1) DE68926899T2 (es)
DK (1) DK474189A (es)
FI (1) FI894551A (es)
HU (1) HUT55445A (es)
IL (1) IL91649A (es)
NO (1) NO893818L (es)
PT (1) PT91808B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068322A1 (en) * 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
TW212184B (es) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH0576385A (ja) * 1990-12-18 1993-03-30 Takeda Chem Ind Ltd キメラ抗体およびその用途
CA2108451A1 (en) * 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
JP6473418B2 (ja) * 2013-10-10 2019-02-20 幸成 加藤 抗ポドプラニン抗体
CN110582514B (zh) * 2017-05-02 2024-03-01 国立研究开发法人国立癌症研究中心 纤溶酶可切割的抗不溶性纤维蛋白的抗体与药物的偶联物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
ES521370A0 (es) * 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
JP2635343B2 (ja) * 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies

Also Published As

Publication number Publication date
AU628857B2 (en) 1992-09-24
IL91649A (en) 1994-10-21
DE68926899D1 (de) 1996-09-05
DE68926899T2 (de) 1997-01-02
FI894551A (fi) 1990-03-28
JP3177776B2 (ja) 2001-06-18
PT91808A (pt) 1990-03-30
KR900004351A (ko) 1990-04-12
FI894551A0 (fi) 1989-09-26
HUT55445A (en) 1991-05-28
EP0363712A2 (en) 1990-04-18
NO893818D0 (no) 1989-09-26
JPH03103175A (ja) 1991-04-30
ATE140930T1 (de) 1996-08-15
EP0363712B1 (en) 1996-07-31
IL91649A0 (en) 1990-04-29
PT91808B (pt) 1995-05-31
CN1041783A (zh) 1990-05-02
DK474189A (da) 1990-03-28
NO893818L (no) 1990-03-28
EP0363712A3 (en) 1990-08-16
DK474189D0 (da) 1989-09-26
AU4174789A (en) 1990-04-05
US5506135A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
GR3018340T3 (en) Method for producing composite cheeses.
EP0598543A3 (en) Method for producing alpha-olefin polymers.
TR27174A (tr) Vinilasetatin üretilmesine mahsus usul.
PH25306A (en) Laminated tile product, method for producing the same, method for installing the same
HK147494A (en) Method for producing at least two.layered articles
IL118149A0 (en) Method for producing heart valves and heart valves produced by the method
ZA925771B (en) Method and apparatus for manufacturing mineral wool, and mineral wool produced thereby.
EP0657753A3 (en) Process for the production of microstructures.
EP0594994A3 (en) Diamond semiconductor and manufacturing method.
EP0761683A4 (en) PROTEIN OR POLYPEPTIDE, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION
ZA967258B (en) Method for the production of synthetic rutile.
EP0602922A3 (en) Process for the preparation of silanes substituted with the dicyloalkyl group.
GB2216211B (en) Insulated pipe joints and methods for forming them.
EP0620284A3 (en) Process for the production of patented steel wire.
EP0602442A3 (de) Verfahren zur Herstellung von höheren, vorwiegend unverzweigten, primären Alkoholen.
ZA9472B (en) Process for producing low molecular-weight poly-1-olefins.
EP0614974A3 (en) Bone - associated transcription control factor-like protein and process for producing the same.
AR242832A1 (es) Polidomas productores de anticuerpos monoclonales hibridos biespecificos contra la fibrina y uk y/o pro uk y metodo para producirlos.
EP0657438A3 (en) Process for the preparation of alkylulfinylbenzamides and 1,2-benzoisothiazol-3-ones.
EP0599142A3 (de) Verfahren zur Herstellung von Immunkonjugaten.
EP0594264A3 (en) Process for the production of block copolymers.
EP0622450A3 (en) Detergent compositions and methods for their manufacture.
EP0664498A4 (en) METHOD OF DESIGNATION OF REGION
EP0152483A4 (en) PROCESS FOR PRODUCING PEPTIDES.
KR950700390A (ko) 강화 탄화수소, 그 제조방법 및 사용방법(fortified hydrocarbon and process for making and using the same)